Jason Stutman’s latest ad for his Technology and Opportunity newsletter ($39/yr, which means they’re really not making money on this unless they get you to upgrade to something else in the future) is yet one more attempt to get us excited because of the rising trend of 5G investment that he thinks will bring “skyrocketing […]
Articles
- Most Relevant
- Most Recent
If newsletter guys know anything, it’s how to sell gold investments — gold has been at the core of the newsletter hype industry since the 1980s, attracting ornery gold bugs every time the gold price rises a bit, so we’re seeing most publishers running quickly to the virtual mailbox with their gold pitches these days… […]
Maybe the scariest thing I can tell you is, “I’m not selling everything.” The drumbeat in my head continues to be one of worry, I continue to be a little bit surprised at how high stocks are going, and how resilient stocks are. But thankfully, I haven’t been acting on those macro worries — because […]
“These 4 “Penny Defense Stocks” Are Primed to Soar on… The Pentagon’s Trillion-Dollar Spending Jackpot” That’s the promise made by the new ads for E.B. Tucker’s Casey Report, which is pitching the stocks that they think will become the “new ‘Military Industrial Complex’” as they grow from small-cap size to compete with the megacaps like […]
Growth stocks get all the attention these days, what with talk of a final “melt up” in the market before things finally return to rationality, and “value stocks” have been floundering for years as they’ve failed to capture the attention of investors… so last fall we saw a lot of predictions about the “turn,” the […]
Over the last several months we’ve seen several ads touting Steve Sjuggerud’s True Wealth Systems, which is apparently a big quantitative screening “supercomputer” that Steve subcontracted to some computer programmers — and which is supposed to identify investing anomalies that he can then write about to his subscribers, who then will profit. And I can’t […]
I haven’t written about any teasers from Dr. Stephen Leeb lately, but this one caught my eye — he’s got not only a made up term for an investment (the “MCR Plan”), but also a made-up term for how you’ll profit from it (“Income Stacking”). So the great readers of Gumshoedom have asked for answers, […]
We are always, always tempted by anything that promises hope to sufferers of Alzheimer’s Disease and their families… not just because we’re humanitarians and love people, and have seen the pain of this disease, but because Alzheimer’s treatment is by far the largest (mostly) unmet medical need in the US, both because the population of […]
Your friendly neighborhood Gumshoe is on vacation this week and celebrating Independence Day, but we’ve gotten so many questions about this pick that we can’t resist sharing it with you. Again. The Motley Fool has hyped up this same pick several times this year — quite profitably so far, though I’ve not been along for […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] “I live in the light of the bright summer […]
Anatabloc at GNC Star ScientificI have been on Anatabloc for two months and it has changed my life completely. Anatabloc nutraceutical supplement available at GNC Thyroid Thyroid / Thyroiditis Overview In the USA alone over 70 million THYROID prescriptions are written at a value of about $2 billion; it’s the 4th most prescribed prescriptions for any disease. In the […]
These kinds of ads always include some huge numbers that sound really, really impressive… here’s a little bit of the intro from the latest ad for Briton Ryle’s The Wealth Advisory: “*Jim T. collected $23,500 last month from ‘backdooring’ Google’s Account *Ron J. ‘backdoored’ $15,804 from Facebook’s Account *Aaron K. pocketed $6,817 last month from […]
I’m sure many of you have seen the “Alpha Bulldogs” ad for Martin Hutchinson’s Permanent Wealth Investor newsletter — the marketing for this one is everywhere, and the ad letters are filled with promise for those who need some income and safety. Hutchinson claims that he only recommends “Alpha Bulldogs that are already legally required […]
If you’re wondering whether it’s interest rates or just “worry about overvaluation or growth” that’s making the stock market go crazy this week, or whether it’s the trade war or political upheaval or something else, well, join the club. There’s some indication that traders are in fear of the “slowdown” that could be caused by […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Ho ho ho! And Happy Christmas to all […]
This week I’m at the Value Investing Congress in New York, so your friendly neighborhood Gumshoe may toss in a teaser unveiling during these couple days if something jumps out at me, but for the most part I’m going to share some of the ideas from the conference that I find appealing, both for free […]
This week I’m at the Value Investing Congress in New York, so your friendly neighborhood Gumshoe may toss in a teaser unveiling during these couple days if something jumps out at me, but for the most part I’m going to share some of the ideas from the conference that I find appealing, both for free […]
I’ve been asked a few questions about the gold stocks in my portfolio, so I thought I’d run through a few of them today and provide whatever updated opinion and assessment I can for you — including a few portfolio adjustments I’ve just made. And, as an added bonus, I’m adding one new gold stock […]
I’ve got a whole passel of things to comment on for you today — I want to update my thoughts on some insurance company stocks that I own and that I touted as beneficiaries of a big switch in the insurance market over the past year or so, check in on a buy and a […]
[ed note: We got a lot of questions about this pitch after we solved a different DeHaemer teaser yesterday, so we’ve brought it up for all to see again. The stock spiked up in the Spring, a few months after this article first ran back in January, but has come back down to a bit […]
I was looking into a couple little eensy teensy microcap stocks that are being touted this week, and I just didn’t have the heart to write about them for you — I do cover microcaps from time to time, but I know that most of you are too experienced and sober to be investing in […]
So… the Fed failed to do anything, which I guess means that the wild predictions about the end of western civilization hitting us on September 18th are going to get pushed off again. Maybe we’ll soon start to see ads about how the next Greater Depression will start on October 28, or December 16…. or, […]
[ed note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who shares his non-investing thoughts with Stock Gumshoe readers a couple times a month. He selects his own topics, and his words and opinions are, of course, his own — you can see his previous commentaries […]
This is the first ticker specific discussion…..if it works, there may be many others. The aim is to have a chronological knowledge diary. If your comment is about ANYTHING other than $ARTH…please DONT post it here. **Please note that this post has been closed to further comment. The discussion on ARTH has moved over to […]
I know, I know, I’m cynical — but yes, we can probably start out by responding to that headline question with a “probably not.” But that doesn’t mean we don’t care what they’re talking about in this latest ad — this time, the pitch comes from Jimmy Mengel for his The Crow’s Nest letter — […]
We’ve got a quickie here that a few folks asked about, and I thought I’d throw it out for you just because there are so many of you who are interested in biotech stocks (and why wouldn’t you be, of course, given the fact that the biotech index would have given you a 350%+ return […]
In light of a interview I watched tonight of Steve Sjuggerud’s forecast on the Yuan becoming the next IMR, I found some challenges to Steve’s interview and would like a comment or rebuttal. These challenges were in the Wall Street Journal: ”To be sure, even if the yuan is recognized by the IMF as a […]
We’ve had a number of questions about this pitch for “The Next Chipotle” from Briton Ryle, so we’re re-posting this solution from December — the stock they’re teasing, ZOES, is still the same, though it reported a great first quarter in early June and the shares popped up on the news (and came back down […]
[ed. note: Michael Jorrin, who I like to call Doc Gumshoe, writes mostly non-financial articles about health topics for our readers a couple times a month — he is not a doctor (he’s a longtime medical writer), he chooses his own topics, and his words and opinions are his own. Enjoy!] It was only a […]
[Ed note: This article was originally published in June, 2013 when the shares of the stock teased, Alnylam (ALNY) were around $30 and the Oxford Club was saying that the first person to live to 1,000 is already alive … now they’re touting it as the holder of the “Magic” Keys to Immortality, but the […]
This article was originally published in late January — Andy Obermueller is teasing Apple suppliers again, hinting that the Apple “Growth Window” will close up on September 30 (presumably when we start freaking out about their next wave of iPhones and iPads, usually introduced around then), and the descriptions of the teased stocks that he […]
Yesterday we looked at Louis Navellier’s pitch about his “bulletproof” stocks to buy — mostly pretty reasonable growth stocks that are priced like growth stocks, but not the crazy hyper-momentum valuations that scare people. Today I thought we’d take a quick moment to ID a couple of the other ideas in his ad. The big […]
We continue to see worrisome commentary about market valuations, with hand-wringing about whether the stock market is overvalued or might be in a bubble… and it can get a bit draining, frankly. Caution is important, diversification is important, but worrying does us little good. Yes, investors are paying a steep price for anticipated growth in […]
Maybe the scariest thing I can tell you is, “I’m not selling everything.” The drumbeat in my head continues to be one of worry, I continue to be a little bit surprised at how high stocks are going, and how resilient stocks are. But thankfully, I haven’t been acting on those macro worries — because […]
Lots of folks are asking about this one, so we’re pulling it to the top of the page again — the article below has not been updated or revised since it ran on March 10, though in the interim the stock teased bumped from $10 to $13 and is now back down below $12, with […]
The basic premise of this ad is pretty familiar — you can get good returns without risk. Isn’t that what everyone wants? Presumably the nitty gritty detail is a little different, but, well, who can think about details when they’re under the hypnotic spell of an expert copywriter who’s weaving a tale about secret accounts […]
Pain management is a huge market in the medical world, as you’re no doubt aware — and buckets of money are pouring down on the many, many little biotech stocks who are trying to develop new pain medications, or to tweak existing medications to make them safer or less likely to be abused. So it’s […]
This ad caught my eye as readers were forwarding it in because it looks like a biotech pitch at first, but quickly morphs into a technology story. The spiel is all about stopping deaths, and about how it’s about time someone put a stop to the unnecessary level of pain and suffering we’re all suffering… […]
[ed. note: Michael Jorrin, who I like to call Doc Gumshoe (he’s a longtime medical writer, not a doctor), writes for us on health and medical issues from time to time — his articles generally are not financial in focus, but he has agreed to the same trading restrictions as our other authors, and, as […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. His bio, past articles, and most recent comments can be seen here. Enjoy!] OUT of the night that covers me, Black as the Pit from pole to pole, I thank […]